Initial Memory Problems Are Linked With a Slower Rate of Decline in Alzheimer’s Disease and Related Dementias

Summary: Initial memory problems are linked with a slower rate of decline in Alzheimer’s disease. Those with symptoms including language difficulties or judgment changes had a more rapid rate of decline than those with memory problems alone.

Source: Clevland Clinic

New Cleveland Clinic research finds that initial memory problems are linked with a slower rate of decline in Alzheimer’s disease and related dementias.

The research team analyzed longitudinal data from 2,400 patients in the National Alzheimer Coordinating Center database to compare rates of decline in patients with Alzheimer’s disease, Lewy Body Dementia and mixed dementia.

The study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, found that people with initial symptoms such as language difficulties or judgment changes had a more rapid course of disease than those with memory loss alone.

“This is the first study to evaluate the impact of the nature of early cognitive symptoms on future rate of cognitive decline,” said Jagan Pillai, M.D., of Cleveland Clinic’s Center for Brain Health and lead author of the study.

This shows the outline of a head
Researchers found that people with initial symptoms such as language difficulties or judgment changes had a more rapid course of disease than those with memory loss alone. Image is in the public domain

“These results hold importance in both designing future clinical trials design and individual patient management among dementia patients.”

About this Alzheimer’s disease research news

Author: Press Office
Source: Clevland Clinic
Contact: Press Office – Clevland Clinic
Image: The image is in the public domain

Original Research: Open access.
Initial non‐amnestic symptoms relate to faster rate of functional and cognitive decline compared to amnestic symptoms in neuropathologically confirmed dementias” by Jagan A Pillai et al. Alzheimer’s & Dementia


Abstract

Initial non‐amnestic symptoms relate to faster rate of functional and cognitive decline compared to amnestic symptoms in neuropathologically confirmed dementias

Introduction

The relationship between initial cognitive symptoms and subsequent rate of clinical decline is important in clinical care and the design of dementia clinical trials.

Methods

This retrospective longitudinal, autopsy-confirmed, cohort study among 2426 participants in the National Alzheimer’s Coordinating Center database included Alzheimer’s disease (AD) pathology, n = 1187; Lewy body pathology (LBP), n = 331; and mixed pathology (AD-LBP), n = 904. The predominant initial cognitive symptom was assessed clinically. Linear mixed models evaluated the longitudinal outcome of the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score.

Results

Non-amnestic initial symptoms had a faster rate of decline than amnestic symptoms in all three groups. Language symptoms had a faster rate of decline in all three groups. Executive symptoms had a faster rate of decline than amnestic in AD and AD-LBP. There was a similar trend for visuospatial symptoms in AD-LBP.

Discussion

Initial cognitive symptoms, despite varied underlying pathology, are a predictor of longitudinal functional outcomes among dementias.

Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive our recent neuroscience headlines and summaries sent to your email once a day, totally free.
We hate spam and only use your email to contact you about newsletters. You can cancel your subscription any time.
  1. How about the extensive short and long term memory loss as a result of the mental health procedure called ECT/ Electroshock? How is it that electrical mechanism of trauma is well known to induce a TBI and systemic short and long term damages, yet when it comes to a psychiatrist inficting this, all reason goes out the window? Why is this the only device and procedure that has not been required to meet FDA standards of safety or even effectiveness? I think this is for several reasons: The FDA experts know full well based on mechanism the damages anticipated, the great deal of money involved, and that who will believe the complaints of psychiatric patient over the word of a psychiatrist? Also our damages that most in medicine are fully aware of, are ignored to protect physicians. My peers have committed suicide, because better to call one “unstable” and may in fact benefit from more ECT verses being entered into a TBI rehabilitation program for testing, suport, and rehabilitation. Dr. Bennett Omalu who recognized CTE in the NFL is now an expert in ECT cases on behalf of plaintiffs. Those of you in medicine who are now no longer employed because of the vaccine and can speak freely of this known harm taking place around this practice, please go on social media platforms and address. If you worked in the field of trauma medicine or psychiatry and have extensive knowledge of this area of trauma then I encourage you to reach out to the law firms involved in an ECT device suit to share what information you know. This is the Baum Hedlund law firm in CA. Given the mental health issues taking place given our times, many are at risk for being offered this. This is fraud at best and we want this issue addressed.

Comments are closed.